Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Fibromyalgia

A new treatment option for fibromyalgia

Nature Reviews Rheumatology volume 5, pages 188–190 (2009)Cite this article

The FDA's approval of milnacipran reflects advances in the development of drugs aimed at modulating pain circuitry in fibromyalgia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lawrence, R. C. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58, 26–35 (2008).

    PubMed  PubMed Central  Google Scholar 

  2. Boomershine, C. S. & Crofford, L. J. A symptom-based approach to pharmacologic management of fibromyalgia. Nat. Rev. Rheumatol. 5, 191–199 (2009).

  3. FDA Center for Drug Evaluation and Research. Savella (milnacipran) label information [online 8 January 2009], http://www.fda.gov/cder/foi/label/2009/022256lbl.pdf (2009).

  4. Clauw, D. J., Mease, P., Palmer, R. H., Gendreau, R. M. & Wang, Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin. Ther. 30, 1988–2004 (2008).

    Article  CAS  PubMed  Google Scholar 

  5. FDA Center for Drug Evaluation and Research. Summary Review for Savella (milnacipran): application #22–256, http://www.fda.gov/cder/foi/summary_review/2009/022256s000SumR.pdf (2009).

  6. Mease, P. J. et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J. Rheumatol. 36, 398–409 (2009).

    Article  CAS  PubMed  Google Scholar 

  7. Mease, P., Palmer, R. H., Rao, S., Zablocki, R. & Qu, P. Improvement in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: results from a dose controlled extension study [abstract #583]. Arthritis Rheum. 58 (Suppl.), S383 (2008).

    Google Scholar 

  8. Stahl, S. M., Grady, M. M., Moret, C. & Briley, M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 10, 732–747 (2005).

    Article  PubMed  Google Scholar 

  9. Heinricher, M. M., Tavares, I., Leith, J. L. & Lumb, B. M. Descending control of nociception: specificity, recruitment and plasticity. Brain Res. Rev. doi:10.1016/j.brainresrev.2008.12.009 (2008).

  10. Vaishnavi, S. N. et al. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol. Psychiatry 55, 320–322 (2004).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. RM Bennett, School of Nursing, Oregon Health & Science University, 3455 SW US Veterans Hospital Road, Portland, OR 97239, USA bennetrob1@comcast.net

Authors and Affiliations

  1. School of Nursing, Oregon Health & Science University, Portland, OR, USA

    Robert M. Bennett

Authors
  1. Robert M. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

R.M. Bennett is a scientific advisor for Cypress Bioscience.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bennett, R. A new treatment option for fibromyalgia. Nat Rev Rheumatol 5, 188–190 (2009). https://doi.org/10.1038/nrrheum.2009.48

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2009.48

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing